Torisel - 2007 FDA approvals

Drug: Torisel (temsirolimus)
Indication: Renal cell carcinoma
Company: Wyeth
Approval Date: May 30, 2007

Scoop: Torisel is an mTOR inhibitor. In in vitro studies using cancer cells, mTOR inhibition blocked the translation of genes that regulate the cell cycle. Torisel improved median overall survival by 49 percent in Phase III compared to interferon-alpha.

More news:
FDA approves Wyeth's Torisel. Report
Wyeth looking for Torisel approvals. Report

Torisel - 2007 FDA approvals
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.